Table 3.

Nonhematologic treatment–related adverse events reported by at least 10% patients

CategoryAdverse eventAll grades n (%)Grade 1 n (%)Grade 2 n (%)Grade 3 n (%)Grade 4 n (%)
CardiacHypertension5 (10)2 (4)2 (4)1 (2)0 (0)
ConstitutionalFatigue27 (54)9 (18)10 (20)8 (16)0 (0)
Fever—no infection5 (10)4 (8)1 (2)0 (0)0 (0)
Rigors/chills7 (14)7 (14)(0)0 (0)0 (0)
Weight loss10 (20)2 (4)8 (16)0 (0)0 (0)
DermatologyAcneiform rash23 (46)10 (20)10 (20)3 (6)0 (0)
Alopecia11 (22)9 (18)2 (4)0 (0)0 (0)
Dry skin8 (16)8 (16)0 (0)0 (0)0 (0)
Hand-foot skin reaction30 (60)9 (18)13 (26)8 (16)0 (0)
Rash/desquamation erythema14 (28)4 (8)5 (10)4 (8)1 (2)
EndocrineHypothyroidism (TSH >5.0 mU/L)11 (22)7 (14)4 (8)0 (0)0 (0)
High PTH (>11 pmol/L)13 (26)13 (26)0 (0)0 (0)0 (0)
GastrointestinalAnorexia17 (34)9 (18)6 (12)2 (4)0 (0)
Constipation8 (16)8 (16)(0)0 (0)0 (0)
Diarrhea42 (84)21 (42)14 (28)7 (14)0 (0)
Dry mouth syndrome12 (24)10 (20)2 (4)0 (0)0 (0)
Nausea21 (42)14 (28)6 (12)1 (2)0 (0)
Mucositis/stomatitis-oral cavity14 (28)8 (16)4 (8)2 (4)0 (0)
Taste alteration/dysgeusia13 (26)11 (22)2 (4)0 (0)0 (0)
Vomiting12 (24)7 (14)4 (8)1 (2)0 (0)
HemorrhageNose7 (14)6 (12)1 (2)0 (0)0 (0)
OcularDry eye syndrome6 (12)6 (12)0 (0)0 (0)0 (0)
PainHeadache8 (16)2 (4)6 (12)0 (0)0 (0)
PulmonaryCough13 (26)8 (16)5 (10)0 (0)0 (0)
Dyspnea6 (12)5 (10)0 (0)1 (2)0 (0)
Voice change/hoarseness15 (30)15 (30)0 (0)0 (0)0 (0)

Abbreviations: TSH, thyroid-stimulating hormone; PTH, parathyroid hormone.